Literature DB >> 24293163

Gastric bypass surgery may improve beta cell apoptosis with ghrelin overexpression in patients with BMI ≥ 32.5 kg/m(2.).

Jian Yang1, Xiao Feng, Shuzhe Zhong, Yong Wang, Jingang Liu.   

Abstract

BACKGROUND: Roux-en-Y gastric bypass (RYGB) surgery can lead to long-term remission of type 2 diabetes mellitus, depending on changes in weight and circulating levels of gut hormones. The general objectives of this study were to evaluate changes in plasma levels of the ghrelin gene products following RYGB surgery and to determine the role of ghrelin in inhibiting apoptosis of INS-1 cells induced by hyperglycemia.
METHODS: Sixteen obese Chinese patients with type 2 diabetes mellitus who underwent gastric bypass surgery were assessed in this investigation. Blood plasma levels of acylated ghrelin (AG), unacylated ghrelin (UAG), and obestatin (OB) were measured both before and 12 months after RYGB surgery. To determine the effect of ghrelin on inhibition of apoptosis, INS-1 cells were cultured in a high glucose concentration and treated with AG, UAG, or OB. Cell viability was assessed using the MTT assay, and apoptosis was evaluated by flow cytometry with Annexin-V FITC/PI double staining and transmission electron microscopy. Intracellular calcium trafficking was assessed using flow cytometry and confocal microscopy. All the data was processed using the SPSS statistical package and expressed as means ± SD, with p < 0.05 considered statistically significant.
RESULTS: Fasting and postprandial plasma levels of AG, UAG, and OB were significantly elevated 1 year after RYGB surgery. Mean fasting plasma AG, UAG, and OB increased from preoperative levels of 37.0, 462, and 69.4 pg/mL, respectively, to 61.4, 804, and 112 pg/mL (with p < 0.05) 1 year after surgery. Mean 120-min postprandial plasma AG, UAG, and OB increased from preoperative levels of 23.8, 287, and 53.8 pg/mL, respectively, to 39.7, 516, and 69.0 pg/mL (with p < 0.05) postoperatively. After a 1-week culture of INS-1 beta cell in high glucose, peptide treatment showed increased cell survival by 69 % (AG), 60 % (UAG), and 73 % (OB) and decreased apoptosis by 49 % (AG), 37 % (UAG), and 38 % (OB) compared to cells cultured in high glucose without peptides, respectively (with p < 0.05). Treatment with AG, UAG, and OB inhibited intracellular calcium mobilization and intramitochondrial calcium accumulation in INS-1 cells to protect the cells from hyperglycemia-induced apoptosis.
CONCLUSIONS: The remission of diabetes following RYGB surgery seems to be associated with increased plasma levels of AG, UAG, and OB. Moreover, the ghrelin gene products probably protect β cells by maintaining calcium homeostasis. Additional mechanisms, currently unclear, are likely to be involved as well.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24293163     DOI: 10.1007/s11695-013-1135-4

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  63 in total

1.  Uncoupling protein-2 negatively regulates insulin secretion and is a major link between obesity, beta cell dysfunction, and type 2 diabetes.

Authors:  C Y Zhang; G Baffy; P Perret; S Krauss; O Peroni; D Grujic; T Hagen; A J Vidal-Puig; O Boss; Y B Kim; X X Zheng; M B Wheeler; G I Shulman; C B Chan; B B Lowell
Journal:  Cell       Date:  2001-06-15       Impact factor: 41.582

2.  The decrease in plasma ghrelin concentrations following bariatric surgery depends on the functional integrity of the fundus.

Authors:  Gema Frühbeck; Alberto Diez-Caballero; M Jesús Gil; Inés Montero; Javier Gómez-Ambrosi; Javier Salvador; Javier A Cienfuegos
Journal:  Obes Surg       Date:  2004-05       Impact factor: 4.129

3.  Calcium channel blocker (diltiazem) inhibits apoptosis of vascular smooth muscle cell exposed to high glucose concentration through lectin-like oxidized low density lipoprotein receptor-1 (LOX-1) pathway.

Authors:  Achmad Rudijanto
Journal:  Acta Med Indones       Date:  2010-04

4.  Ghrelin is a growth-hormone-releasing acylated peptide from stomach.

Authors:  M Kojima; H Hosoda; Y Date; M Nakazato; H Matsuo; K Kangawa
Journal:  Nature       Date:  1999-12-09       Impact factor: 49.962

5.  Glucose sensitivity and metabolism-secretion coupling studied during two-year continuous culture in INS-1E insulinoma cells.

Authors:  Arnaud Merglen; Sten Theander; Blanca Rubi; Gaelle Chaffard; Claes B Wollheim; Pierre Maechler
Journal:  Endocrinology       Date:  2003-10-30       Impact factor: 4.736

6.  How do we define cure of diabetes?

Authors:  John B Buse; Sonia Caprio; William T Cefalu; Antonio Ceriello; Stefano Del Prato; Silvio E Inzucchi; Sue McLaughlin; Gordon L Phillips; R Paul Robertson; Francesco Rubino; Richard Kahn; M Sue Kirkman
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

7.  Establishment of 2-mercaptoethanol-dependent differentiated insulin-secreting cell lines.

Authors:  M Asfari; D Janjic; P Meda; G Li; P A Halban; C B Wollheim
Journal:  Endocrinology       Date:  1992-01       Impact factor: 4.736

8.  Effect of weight loss by diet or gastric bypass surgery on peptide YY3-36 levels.

Authors:  Blanca Oliván; Julio Teixeira; Mousumi Bose; Baani Bawa; Tangel Chang; Heather Summe; Hongchan Lee; Blandine Laferrère
Journal:  Ann Surg       Date:  2009-06       Impact factor: 12.969

9.  Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety.

Authors:  C M Borg; C W le Roux; M A Ghatei; S R Bloom; A G Patel; S J B Aylwin
Journal:  Br J Surg       Date:  2006-02       Impact factor: 6.939

10.  Calcium entry mediates hyperglycemia-induced apoptosis through Ca(2+)/calmodulin-dependent kinase II in retinal capillary endothelial cells.

Authors:  Jun Li; Peipei Wang; Songping Yu; Zhi Zheng; Xun Xu
Journal:  Mol Vis       Date:  2012-09-20       Impact factor: 2.367

View more
  9 in total

1.  Ghrelin protected neonatal rat cardiomyocyte against hypoxia/reoxygenation injury by inhibiting apoptosis through Akt-mTOR signal.

Authors:  Lifeng Wang; Yingjie Lu; Xian Liu; Xiaoyun Wang
Journal:  Mol Biol Rep       Date:  2017-03-09       Impact factor: 2.316

2.  Changes in Bone Metabolism After Sleeve Gastrectomy Versus Gastric Bypass: a Meta-Analysis.

Authors:  Zhao Tian; Xin-Tong Fan; Shi-Zhen Li; Ting Zhai; Jing Dong
Journal:  Obes Surg       Date:  2020-01       Impact factor: 4.129

Review 3.  Changes in Bone Metabolism in Morbidly Obese Patients After Bariatric Surgery: A Meta-Analysis.

Authors:  Cong Liu; Dan Wu; Jing-Fan Zhang; Duo Xu; Wan-Feng Xu; Yu Chen; Bing-Yang Liu; Ping Li; Ling Li
Journal:  Obes Surg       Date:  2016-01       Impact factor: 4.129

Review 4.  Potential Hormone Mechanisms of Bariatric Surgery.

Authors:  Georgios K Dimitriadis; Manpal S Randeva; Alexander D Miras
Journal:  Curr Obes Rep       Date:  2017-09

Review 5.  Endocrine implications of bariatric surgery: a review on the intersection between incretins, bone, and sex hormones.

Authors:  Isabel Casimiro; Susan Sam; Matthew J Brady
Journal:  Physiol Rep       Date:  2019-05

6.  Bypassed and Preserved Stomach Resulted in Superior Glucose Control in Sprague-Dawley Rats with Streptozotocin-Induced Diabetes.

Authors:  Jason Widjaja; Ponnie Robertlee Dolo; Qiang Zhang; Libin Yao; Chao Li; Jian Hong; Hui Wang; Song Meng; Yong Shao; Xiaocheng Zhu
Journal:  Sci Rep       Date:  2019-07-10       Impact factor: 4.379

7.  Translational aspects of body image research for obesity-related quality of life and weight loss maintenance post-bariatric surgery.

Authors:  Marie L Caltabiano
Journal:  Ann Transl Med       Date:  2020-03

8.  Adiponectin/SIRT1 Axis Induces White Adipose Browning After Vertical Sleeve Gastrectomy of Obese Rats with Type 2 Diabetes.

Authors:  Lei Liu; Tianyi Zhang; Jingyao Hu; Rui Ma; Bing He; Mofei Wang; Yong Wang
Journal:  Obes Surg       Date:  2020-04       Impact factor: 4.129

9.  Metabolic surgery in China: present and future.

Authors:  Yinfang Tu; Yuqian Bao; Pin Zhang
Journal:  J Mol Cell Biol       Date:  2021-07-07       Impact factor: 6.216

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.